Clinical trial
An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.
NCT01023685 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.
- Lead sponsor
- Novartis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- February 29, 2012
- Enrollment
- 24 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.